Abstract
One of the hallmarks of cystic fibrosis (CF) lung disease is the presence of intense, neutrophil-dominated airway inflammation, and many researchers have focused on developing therapies to reduce inflammation in CF lung disease. Systemic corticosteroids can delay progression of lung disease, but at the cost of unacceptable side effects. Inhaled corticosteroids are widely used, but their efficacy has yet to be demonstrated in a controlled fashion. Ibuprofen has also been shown to delay disease progression, but its use has been limited by the need to obtain individual pharmacokinetics and concern about side effects. Other treatments with potential anti-inflammatory effects include pentoxifylline, leukotriene antagonists, docosahexaenoic acid, and azithromycin. Few, if any, large clinical studies of these therapies have been published, but several are presently underway. Because neutrophil elastase appears to be a key mediator of tissue damage in CF lung disease, antielastase compounds have also been studied, including alpha-1-protease inhibitor, secretory leukocyte protease inhibitor, and small molecule inhibitors. There have been no large-scale controlled trials of these therapies in CF. More recently, investigators have focused on cytokine modulation, using either interleukin-10 or interferon gamma. Some complementary and alterative medicine therapies may also have anti-inflammatory effects, although their clinical value has yet to be demonstrated in a rigorously-controlled fashion. In summary, numerous anti-inflammatory therapies have been applied to CF lung disease, but more large, well-controlled studies will need to be performed to determine their true clinical usefulness.
Similar content being viewed by others
References
Konstan, M.W. and Berger, M. (1997), Pediatr. Pulmonol. 24,137–142.
Amstrong, D., et al. (1997), Am. J. Resp. Crit. Care Med. 156,1197–1203.
Khan, T.Z., et al. (1995), Am. J. Resp. Crit. Care Med. 151,1075–1082.
Auerbach, H.S., et al. (1985), Lancet, 686–688.
Eigen, H., et al. (1995), J. Pediatr. 126,515–23.
Lai, H.C., et al. (2000), N. Engl. J. Med. 342,851–859.
Donati, M.A., Haver, K., Gerson, W., Klein, M., McLaughlin, F.J., and Wohl, M.E.B. (1990), Pediatr. Pulmonol. 5,A322.
Barnes, P.J., Pedersen, S., and Busse, W.W. (1998), Am. J. Resp. Crit. Care Med. 157,S1–53.
Dauletbaev, N., et al. (1999), Eur. Respir. J. 14,1150–1155.
Nikolaizik, W.H. and Schoni, M.H. (1996), J. Pediatr. 128,271–274.
van Haren, E.H., et al. (1995), Respir. Med. 89,209–214.
Dezateux, C., Walters, S., and Balfour-Lynn, I. Inhaled corticosteroids for cystic fibrosis (Cochrane Review), in The Cochrane Library, Issue 1, 2001. Oxford: Update Software.
Levin, L.S. and Boston, B.A. (2000), J. Pediatr. 137,450–454.
Konstan, M.W., et al. (1999), Pediatr. Pulmonol. 28,242–247.
Brown, K.A. and Collins, A.J. (1977), Ann. Rheum. Dis. 36,239–243.
Maderazo, E.G., Breaux, S.P., and Woronick, C.L. (1984), J. Pharm. Sci. 73, 1403–1496.
Shimanuki, T., Nakamura, R.M., and diZerega, G.S. (1985), Agents Actions 17, 80–83.
Konstan, M.W., Vargo, K.M., and Davis, P.B. (1990), Am. Rev. Respir. Dis. 141,186–192.
Konstan, M.W., et al. (1995), N. Engl. J. Med. 332,848–854.
Oermann, C.M., Sockrider, M.M., and Konstan, M.W. (1999), Chest 115, 1053–1058.
Kovesi, T.A., Swartz, R., and MacDonald, N. (1998), N. Engl. J. Med. 338,65–66.
Sullivan, G.W., et al. (1988), Infect. Immun. 56,1722–1729.
Beutler, B. and Cerami, A. (1987), N. Engl. J. Med. 316,379–385.
Kelly, N., Clee, S., and Nakielna, B. (1995), Clin. Diagn. Lab. Immunol. 2,499–502.
Salva, P.S., et al. (1996), Pediatr. Pulmonol. 21,11–19.
Greally, P., et al. (1993), Arch. Dis. Child. 68,389–392.
Aronoff, S.C., et al. (1994), J. Pediatr. 125,992–997.
Drazen, J.M., Israel, E., and O'Byrne, P.M. (1999), N. Engl. J. Med. 340,197–206.
Greally, P., et al. (1994), J. Allergy Clin. Immunol. 93,100–107.
Morice, A.H., Kastelik, J.A., and Aziz, I. (2001), Thorax 56,244–245.
Farrell, P.M., et al. (1985), Pediatr. Res. 19,104–109.
Freedman, S.D., et al. (2000), Curr. Opin. Pulm. Med. 6,530–532.
Freedman, S.D., et al. (1999), Proc. Natl. Acad. Sci. USA 96,13,995–14,000.
Greener, M. (2000), Mol. Med. Today 6,47–48.
Klein, J.O. (1997), Pediatr. Infect. Dis. J. 16,427–431.
Jaffe, A. and Bush, A. (2001), Pediatr. Pulmonol. 31,464–473.
Oda, H., et al. (1994), Chest 106,1116–1123.
Khair, O.A., et al. (1995), Eur. Respir. J. 8,1451–1457.
Kudoh, S. (1998), Curr. Opin. Pulm. Med. 4,116–121.
Koyama, H. and Geddes, D.M. (1997), Thorax 52,915–918.
Hoiby, N. (1994), Thorax 49,531–532.
Jaffe, A., et al. (1998), Lancet 351,420.
Foreman, J.C. and Pearce F.L. Cromolyn and nedocromil, in Allergy: Principles and Practice, 4th ed., Middleton, J.E. et al., eds., Mosby-Year Book, Inc., St. Louis, 1993, pp. 926–940.
Sivan, Y., et al. (1990), J. Allergy Clin. Immunol. 85, 649–654.
Cystic Fibrosis Foundation. (1998), Patient Registry Annual Data Report, Bethesda, MD.
Konstan, M.W., et al. (1994), Am. J. Respir. Crit. Care Med. 150,448–454.
Birrer, P., et al. (1994), Am. J. Respir. Crit. Care Med. 150,207–213.
Beatty, K., Bieth, J., and Travis, J. (1980), J. Biol. Chem. 270,3931–3934.
Ying, Q.L., Kemme, M., and Simon, S.R. (1996), Am. J. Respir. Cell Mol. Biol. 15,283–291.
Ying, Q.L. and Simon, S.R. (2000), Am. J. Respir. Cell Mol. Biol. 23,506–513.
Desrochers, P. and Weiss, S. (1988), J. Clin. Investig. 81,1646–1650.
Van-Seuningen, I. and Davril, M. (1991), Biochem. Biophys. Res. Commun. 179,1587–1592.
Ying, Q.L. and Simon, S.R. (1995), Am. J. Respir. Cell Mol. Biol. 13,703–711.
Ying, Q., et al. (1997), Am. J. Physiol. 272,L533-L541.
McElvaney, N.G., et al. (1991), Lancet 337,392–394.
McElvaney, N., et al. (1993), Am. Rev. Respir. Dis. 148,1056–1060.
Quon, C.Y., et al. (2000), Pediatr. Pulmonol. S20,250.
Abrahamson, B., et al. (1999), Pediatr. Pulmonol. S19,317.
Delacourt, C., et al. (1995), Am. J. Respir. Crit. Care Med. 152,765–774.
Ren, C.L., et al. (1997), Pediatr. Pulmonol. 14,318.
Ren, C.L., Bellucci, W.J., and Simon, S.R. (2000), Pediatr. Pulmonol. S20,254.
Borish, L. (1998), J. Allergy Clin. Immunol. 101,293–297.
Chmiel, J.F., et al. (1997), Am. J. Respir. Crit. Care Med. 160,2040–2047.
Bonfield, T.L., et al. (1995), Am. J. Respir. Cell Mol. Biol. 13,257–261.
Romagnani, S. (2000), Ann. Allergy Asthma Immunol. 85,9–18.
Moser, C., et al. (1997), Apmis 105,838–842.
Johansen, H.K., et al. (1996), Clin. Exp. Immunol. 103,212–218.
Moss, R.B., Hsu, Y.P., and Olds, L. (2000), Clin. Exp. Immunol. 120,518–525.
Wojnarowski, C., et al. (1999), Eur. Respir. J. 14,1136–1144.
Bonfield, T., et al. (1995), Am. J. Respir. Crit. Care Med. 152,2111–2118.
Pisetsky, D.S. (2000), N. Engl. J. Med. 342,810–811.
Moreland, L.W., et al. (1997), N. Engl. J. Med. 337,141–147.
Targan, S.R., et al. (1997), N. Engl. J. Med. 337,1029–1035.
Fisher, C.J., Jr, et al. (1996), N. Engl. J. Med. 334,1697–1702.
Grau, G.E. and Maennel, D.N. (1997), Nat. Med. 3,1193–1195.
Eisenberg, D.M., et al. (1998), JAMA 280,1569–1575.
Ren, C.L., et al. (1998), Pediatr. Pulmonol. S17,405.
Li, X.M., et al. (2000), J. Allergy Clin. Immunol. 106,660–668.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ren, C.L. Use of modulators of airways inflammation in patients with CF. Clinic Rev Allerg Immunol 23, 29–39 (2002). https://doi.org/10.1385/CRIAI:23:1:029
Issue Date:
DOI: https://doi.org/10.1385/CRIAI:23:1:029